SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report: August 13, 2002
US ONCOLOGY, INC.
-----------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware 0-26190 84-1213501
- ---------------- ------------ -------------------
(State or Other (Commission (I.R.S.Employer
Jurisdiction of File Number) Identification No.)
Incorporation
or Organization)
16825 Northchase Drive, Suite 1300
Houston, Texas
77060
--------------------------------
(Address of Principal Executive Offices)
(Zip Code)
Registrant's Telephone Number, Including Area Code: (832) 601-8766
Item 9. REGULATION FD DISCLOSURE
On August 13, 2002, R. Dale Ross, Chairman of the Board and Chief Executive
Officer of US Oncology, Inc. (the "Corporation"), and Bruce D. Broussard, Chief
Financial Officer of the Corporation, each filed with the Securities and
Exchange Commission (the "SEC") a statement under oath regarding facts and
circumstances relating to the Securities Exchange Act filings of the
Corporation, as required by the SEC's Order Requiring the Filing of Sworn
Statements Pursuant to Section 21(a)(1) ofthe Securities Exchange Act of 1934
(File No. 4-460, June 27, 2002).
The statements are attached to this report as exhibits.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
c) Exhibits
99.1 STATEMENT UNDER OATH OF CHIEF EXECUTIVE OFFICER REGARDING FACTS AND
CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS
99.2 STATEMENT UNDER OATH OF CHIEF FINANCIAL OFFICER REGARDING FACTS AND
CIRCUMSTANCES RELATING TO EXCHANGE ACT FILINGS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: August 13, 2002
US ONCOLOGY, INC.
By: Bruce D. Broussard
-------------------------
Bruce D. Broussard
Chief Financial Officer